Project Grant R03HL183012
- This $2.1M project grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a three-year prospective cohort study designed to develop and validate computational and clinical tools for understanding variability in sickle cell disease (SCD) pain experiences. Funded through the NIH HEAL Initiative, Duke University will conduct research utilizing the Globin Research Network for Data and Discovery...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...
- This $764,659 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the mechanisms underlying neuropathic spontaneous pain. The key objectives are to characterize the role of local vascular movement in triggering neuropathic spontaneous pain, determine how mechanoreceptors in sensory neurons contribute...
- This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of Schwann cell PIEZO1 in pain sensation. The key objectives are to: 1) develop and validate adeno-associated virus (AAV) vectors for selective inhibition of Schwann cell PIEZO1, and 2) determine the sensory effects of Schwann cell...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded a $4.04 million Project Grant to the University of Texas at Dallas for a three-year initiative (September 1, 2025 through August 31, 2028) to identify and validate therapeutic targets for chronic pain treatment. The project leverages a CRISPR-based functional genomic screening platform developed by collaborating researchers at the University of Sydney and an extensive human dorsal root ganglion...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $6,522,833 Project Grant to The Leland Stanford Junior University to conduct a mechanistic randomized clinical trial investigating the central and peripheral nervous system mechanisms of pain relief induced by peripheral nerve stimulation (PNS) for the treatment of refractory chronic neuropathic pain. The 3-year study, funded under the NIH HEAL Initiative's CFDA 93.279 Drug Abuse and Addiction Research Programs, aims...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $376,310 to the University of North Carolina at Chapel Hill to develop the necessary documents and procedures to conduct a 16-week randomized controlled trial. The trial will test the efficacy and biochemical mechanisms of a dietary intervention involving increasing omega-3 fatty acids (EPA...
- Federal Cooperative Agreement Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Cooperative Agreement valued at $2,850,366 to the Regents of the University of Michigan on September 19, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Sequential, Multiple Assignment, Randomized Trial (SMART) design study addressing personalized treatment approaches for chronic low back pain (CLBP). The primary deliverable is the development...
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
- This Project Grant award, with an ID of R01DE032676, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $2,372,115 award, spanning from July 2024 to June 2027, supports research to identify and validate the lysophosphatidic acid (LPA)/LPA receptor (LPAR) signaling pathway as a novel target for the treatment of temporomandibular disorder (TMD) pain. The primary research objectives are to: 1)...
PAIN PHENOTYPES IN ADVANCED PERIPHERAL ARTERIAL DISEASE - PROJECT SUMMARY/ABSTRACT LOWER EXTREMITY CHRONIC LIMB-THREATENING ISCHEMIA (CLTI) IS THE MOST ADVANCED FORM OF PERIPHERAL ARTERIAL DISEASE (PAD) AND IS A LIFE-LIMITING CONDITION ASSOCIATED WITH A 25% RISK OF MORTALITY AND A 20% RISK OF MAJOR LIMB AMPUTATION AT ONE YEAR. CLTI IS CHARACTERIZED BY A SPECTRUM OF FINDINGS INCLUDING NON-EXERTIONAL FOOT PAIN ("REST PAIN"), NON-HEALING WOUNDS, AND FRANK GANGRENE, AND PAIN IS A NEARLY UNIVERSAL FEATURE. PAIN IS ALSO AN IMPORTANT FACTOR IN DECISION-MAKING AROUND TREATMENT, WHICH MAY BE NON-PROCEDURAL (PAIN CONTROL AND WOUND CARE), AMPUTATION, OPEN SURGERY (E.G., LEG BYPASS), OR ENDOVASCULAR INTERVENTION (E.G., ANGIOPLASTY AND STENTING). THESE OPTIONS NECESSARILY INVOLVE SUBSTANTIAL TRADEOFFS AMONG PATIENT GOALS SUCH AS MOBILITY, INVASIVENESS OF TREATMENT, LIKELIHOOD OF LIMB SALVAGE, AND POST-TREATMENT PAIN. DESPITE THE CENTRALITY OF PAIN IN PRESENTATION AND DECISION-MAKING, TREATMENT GUIDELINES NEGLECT PAIN AS AN OUTCOME AND FOCUS ON RESTORATION OF ARTERIAL PERFUSION TO ACHIEVE LIMB SALVAGE. THE UNDERLYING ASSUMPTION THAT TREATMENT OF THE UNDERLYING ARTERIAL INSUFFICIENCY WILL TREAT PAIN IS POORLY FOUNDED. CLINICAL OBSERVATION SUGGESTS THAT IN MANY CASES PAIN IN CLTI IS DRIVEN BY MECHANISMS INDEPENDENT OF ARTERIAL PERFUSION; HOWEVER, UNDERSTANDING PAIN IN CLTI HAS NOT BEEN A FOCUS OF RESEARCH: THERE ARE 0 ENGLISH-LANGUAGE PUBLICATIONS SYSTEMATICALLY CHARACTERIZING PAIN AND ITS FEATURES. FURTHERMORE, IN A STUDY OF PAD PATIENTS FEWER THAN HALF OF PATIENTS USED NON-OPIOID ADJUNCTS (E.G., GABAPENTIN) FOR PAIN CONTROL, SUGGESTING BOTH A LACK OF A SYSTEMATIC APPROACH TO PAIN MANAGEMENT AS WELL AS A LACK OF UNDERSTANDING OF PAIN MECHANISMS. PRECISION TREATMENT OF PAIN AND INCORPORATION OF PAIN INTO PROGNOSTICATION AND PATIENT-CENTERED DECISION-MAKING IS IMPOSSIBLE WITHOUT A RIGOROUS REAL-WORLD CHARACTERIZATION OF PAIN IN PATIENTS WITH CLTI INCLUDING ITS FEATURES, SUCH AS SEVERITY, FREQUENCY, AND ASSOCIATIONS WITH PATIENT AND DISEASE-RELATED FACTORS. THIS KNOWLEDGE GAP DIRECTLY CONTRIBUTES TO DEFICITS IN EFFECTIVE DECISION-MAKING AROUND CLTI TREATMENT AND OPTIMAL PAIN MANAGEMENT. THEREFORE, WE PROPOSE TO SYSTEMATICALLY CHARACTERIZE PAIN, INCLUDING IDENTIFICATION OF CLUSTERS OF PAIN FEATURES ("PAIN PHENOTYPES") IN PATIENTS LIVING WITH CLTI AND TO IDENTIFY PATIENT AND CLINICAL FACTORS ASSOCIATED WITH THESE PHENOTYPES. TO ACCOMPLISH THIS, WE WILL RECRUIT 100 PATIENTS LIVING WITH CLTI FACING TREATMENT TO 1) CHARACTERIZE PAIN USING VALIDATED INSTRUMENTS (E.G., GRADED CHRONIC PAIN SCALE) AND TO DETERMINE IF PHENOTYPES EXIST AND 2) DETERMINE THE ASSOCIATION OF PHENOTYPES WITH PATIENT (E.G., SEX) AND DISEASE FEATURES (E.G., CLTI STAGE). THIS WORK WILL CONTRIBUTE MEANINGFULLY TO MY DEVELOPMENT AS A LEADER IN PATIENT-CENTERED OUTCOMES AND DECISION-MAKING AROUND CLTI. MOST IMPORTANTLY, THIS PROPOSAL LAYS THE GROUNDWORK FOR AN R01 FOCUSED ON 1) UNDERSTANDING THE ASSOCIATION BETWEEN PAIN FEATURES AND PHENOTYPES AND CLTI PROGNOSIS, AND 2) A GRANULAR UNDERSTANDING OF PAIN MECHANISMS USING QUANTITATIVE SENSORY TESTING AND OTHER TOOLS WITH A VIEW TOWARDS DEVELOPING GUIDELINES FOR PRECISION PAIN TREATMENT IN PATIENTS SUFFERING FROM CLTI.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($114k) | 4/9/26 | ||
| Not listed | $114.4k | 4/2/26 |